Sprint Bioscience
Business Services · Sweden · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Hälsovägen 7, Huddinge, Stockholm, 141 5...Phone Number
+46 84114455Website
www.sprintbioscience.comRevenue
<$5 MillionStock Symbol
SPRINTIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Sprint Bioscience
Sprint Bioscience is a pharmaceutical company focused on developing innovative drug candidates aimed at providing new treatment options for cancer. The company utilizes a fragment-based drug development approach to efficiently create drug programs that are licensed to global pharmaceutical companies during the preclinical phase. With a significant need for new treatments for hard-to-treat cancers, Sprint Bioscience sees substantial commercial potential in its offerings. The company actively engages in partnerships and collaborations to expand its research and development efforts.Explore more
Sprint Bioscience Org Chart
CA
Administrative Assistant
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sprint Bioscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Sprint Bioscience launches new products
Website visits: Recent activity has been detected on your website
Check if Sprint Bioscience has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Sprint Bioscience
Check out if Sprint Bioscience is spiking on competitors!
Sprint Bioscience, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Sprint Bioscience recently announced quarterly report
Click to see if Sprint Bioscience had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Sprint Bioscience has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Sprint Bioscience is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Sprint Bioscience is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Sprint Bioscience.
Sprint Bioscience Tech Stack
A closer look at the technologies used by Sprint Bioscience
See more technologies
Sprint Bioscience News & Media
BioStock: Sprint Bioscience maintains focus on developing the portfolio
With the activities for 2022 in full swing, Sprint Bioscience publishes the report for the year’s first quarter where we can note a continued focus on developing the programs in the portfolio. The company will begin presenting the latest internal program in the portfolio to potential partners and a scientific council has been appointed to support the future development. BioStock contacted the company’s CEO Erik Kinnman to get his thoughts on the first quarter. ReadSprint Bioscience initiates marketing of an additional cancer drug program
Sprint Bioscience announces today that it is starting to market the DISA program to potential partners and, following a series of research advances, reveals the cancer drug program's target protein, TREX1. The goal of the program, currently in the preclinical phase, is to develop drugs that inhibit the protein TREX1 in order to enhance the effect of immuno-oncological therapy, radiation therapy and chemotherapy in the treatment of cancer. The company will initiate discussions with potentialBioStock: A new cancer project in Sprint Bioscience’s portfolio
In connection with the rights issue this summer, the biotechnology company Sprint Bioscience promised further investments in expanding the development portfolio. Now, about a week after completing the issue, the company has announced NIMA, a cancer project that targets a tumour’s microenvironment to affect the cancer’s ability to grow while at the same time making it easier for the immune system to attack it directly. Read the full article at biostock.se: https://www.biostock.se/en/2021/09/a-newSprint Bioscience adds new cancer drug program to its project portfolio
Sprint Bioscience AB (publ) announces today that the company is broadening its pipeline with an additional drug program for the treatment of solid tumors. The program goes by the program name NIMA and aims to develop drugs to inhibit a naturally occurring protein that is associated with poor survival in several different forms of cancer. An important aspect of the development of a tumor is that the cancer cells can affect their environment to facilitate
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sprint Bioscience
Sign Up For FreeTo access detailed company insights
Sprint Bioscience is a pharmaceutical company focused on developing innovative drug candidates aimed at providing new treatment options for cancer. The company utilizes a fragment-based drug development approach to efficiently create drug programs that are licensed to global pharmaceutical companies during the preclinical phase. With a significant... Read More
